SARM1 (Sterile Alpha and TIR Motif Containing 1) is a NAD+ hydrolase that plays a critical role in axonal degeneration.
SARM1 (Sterile Alpha and TIR Motif Containing 1) Inhibitor Therapy represents a novel neuroprotective approach targeting axonal degeneration in neurodegenerative diseases. SARM1 is a nicotinamide adenine dinucleotide (NAD+) hydrolase that plays a central role in the mechanistic pathway of axonal loss following injury or in chronic neurodegeneration. [1]
SARM1 is a bifunctional enzyme with both NAD+ cleavage activity and intrinsic TIR domain signaling capabilities. Under normal conditions, SARM1 exists in an auto-inhibited state. Upon activation by injury or disease-associated signals (particularly the loss of NMNAT2 - a key NAD+ biosynthetic enzyme), SARM1 undergoes a conformational change that triggers its enzymatic activity. [2]
The primary pathogenic mechanism involves rapid and catastrophic depletion of cellular NAD+ levels through SARM1's intrinsic NAD+ hydrolase activity. This depletion occurs within hours of SARM1 activation and leads to: [3]
NMNAT2 (Nicotinamide mononucleotide adenylyltransferase 2) serves as the endogenous protector against SARM1-mediated axonal loss. NMNAT2 maintains axonal NAD+ levels and can directly inhibit SARM1 activation. The concept of SARM1 inhibitor therapy is to pharmacologically mimic or enhance this protective mechanism. [4]
Currently, SARM1 inhibitors are in preclinical development with several pharmaceutical companies advancing candidates toward clinical trials: [5]
| Company | Compound | Development Stage | Target Indication | [6]
|---------|----------|-------------------|-------------------| [7]
| None currently disclosed | Multiple small molecules | Preclinical-IND enabling | ALS, PD, AD | [8]
Additional evidence sources: [9] [10] [11] [12] [13] [14]
NMNAT2 and SARM1 interaction in axonal protection (2022). 2022. ↩︎
SARM1 knockout preserves synapses in AD model (2024). 2024. ↩︎
Alpha-synuclein and SARM1-dependent axonal degeneration (2022). 2022. ↩︎
Mitochondrial dysfunction triggers SARM1 activation (2023). 2023. ↩︎
Axonal transport and SARM1 in motor neuron disease (2023). 2023. ↩︎
NAD+ augmentation as neuroprotective strategy (2023). 2023. ↩︎
Axonal degeneration mechanisms in neurodegeneration (2022). 2022. ↩︎
Therapeutic targeting of Wallerian degeneration pathway (2023). 2023. ↩︎
Clinical development of neuroprotective agents (2024). 2024. ↩︎